← back to search

Helen Ma

University of California System · US
🔎 Find collaborators in Hematology · Pathology and Forensic Medicine →
Search 5.9M scientists by topic, h-index, country & funding — free.
Area of research
Hematology · Pathology and Forensic Medicine
Research interest
Research interests include Lymphoma Diagnosis and Treatment, Acute Myeloid Leukemia Research, Chronic Lymphocytic Leukemia Research, and CAR-T cell therapy research.
h-index
27
citations
4,001
works
155
NIH funding
primary concept
Medicine
email

Recent publications

An individual participant data meta-analysis of psychological interventions for preventing depression relapse
Nature Mental Health 2024cited by 17position: middledoi
Activation of RAS/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemia
Signal Transduction and Targeted Therapy 2022cited by 177position: middledoi
Correction: Activation of RAS/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemia
Signal Transduction and Targeted Therapy 2022cited by 12position: middledoi
Outcomes in patients with aggressive B‐cell non‐Hodgkin lymphoma after intensive frontline treatment failure
Cancer 2019cited by 35position: middledoi
An inhibitor of oxidative phosphorylation exploits cancer vulnerability
Nature Medicine 2018cited by 945position: middledoi
Inhibition of mTORC1/C2 signaling improves anti-leukemia efficacy of JAK/STAT blockade in <i>CRLF2</i> rearranged and/or <i>JAK</i> driven Philadelphia chromosome-like acute B-cell lymphoblastic leukemia
Oncotarget 2018cited by 49position: middledoi
MLL-AF4 Spreading Identifies Binding Sites that Are Distinct from Super-Enhancers and that Govern Sensitivity to DOT1L Inhibition in Leukemia
Cell Reports 2017cited by 92position: middledoi
T-cell lymphomas, a challenging disease: types, treatments, and future
International Journal of Clinical Oncology 2016cited by 43position: firstdoi
MLL-Rearranged Acute Lymphoblastic Leukemias Activate BCL-2 through H3K79 Methylation and Are Sensitive to the BCL-2-Specific Antagonist ABT-199
Cell Reports 2015cited by 153position: middledoi
Mechanisms of Acquired Resistance to Venetoclax in Preclinical AML Models
Blood 2015cited by 7position: middledoi
Combined Targeting of JAK2 with a Type II JAK2 Inhibitor and mTOR with a TOR Kinase Inhibitor Constitutes Synthetic Activity in JAK2-Driven Ph-like Acute Lymphoblastic Leukemia
Blood 2015cited by 4position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Marina Konopleva · Anderson University - South Carolina4 papers (2015–2018)Lina Han · Hebei Medical University3 papers (2015–2018)Hong Mu · Tianjin First Center Hospital3 papers (2015–2018)Kathryn G. Roberts · Dana-Farber Cancer Institute2 papers (2015–2018)Charles G. Mullighan · Dana-Farber Cancer Institute2 papers (2015–2018)Elias Jabbour · The University of Texas MD Anderson Cancer Center2 papers (2015–2018)Sarah K. Tasian · California University of Pennsylvania2 papers (2015–2018)Qi Zhang · Guangzhou University of Chinese Medicine2 papers (2015–2018) · 2 papers (2015–2018) · 2 papers (2015–2018)Nitin Jain · Parul University2 papers (2015–2018)David M. Weinstock · Harvard University2 papers (2015–2018) · 2 papers (2015–2018) · 1 papers (2017–2017)Simon Gilbody · University of York1 papers (2024–2024)Markus Müschen · Yale Cancer Center1 papers (2015–2015)Irene Roberts · Oxford Health NHS Foundation Trust1 papers (2017–2017)Willem Kuyken · University of Glasgow1 papers (2024–2024)Marlies E. Brouwer · Utrecht University1 papers (2024–2024)Olaf Heidenreich · Newcastle University1 papers (2017–2017)
Looking for a research collaborator?
Search millions of scientists by field, institution, impact, and funding status — see their work, find their email, and reach out directly.
Find collaborators in Hematology · Pathology and Forensic Medicine →